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Abstract
Insulin/IGF-1 signaling plays a pivotal role in the regulation of cellular homeostasis through its control of glucose
metabolism as well as due to its effects on cell proliferation. Aberrant regulation of insulin signaling has been repeatedly
implicated in uncontrolled cell growth and malignant transformations. TBC1D3 is a hominoid specific gene previously
identified as an oncogene in breast and prostate cancers. Our efforts to identify the molecular mechanisms of TBC1D3-
induced oncogenesis revealed the role of TBC1D3 in insulin/IGF-1 signaling pathway. We document here that TBC1D3
intensifies insulin/IGF-1-induced signal transduction through intricate, yet elegant fine-tuning of signaling mechanisms. We
show that TBC1D3 expression substantially delayed ubiquitination and degradation of insulin receptor substrate-1 (IRS-1).
This effect is achieved through suppression of serine phosphorylation at S636/639, S307 and S312 of IRS-1, which are key
phosphorylation sites required for IRS-1 degradation. Furthermore, we report that the effect of TBC1D3 on IRS-1:S636/639
phosphorylation is mediated through TBC1D3-induced activation of protein phosphatase 2A (PP2A), followed by
suppression of T389 phosphorylation on p70 S6 kinase (S6K). TBC1D3 specifically interacts with PP2A regulatory subunit
B56c, indicating that TBC1D3 and PP2A B56c operate jointly to promote S6K:T389 dephosphorylation. These findings
suggest that TBC1D3 plays an unanticipated and potentially unique role in the fine-tuning of insulin/IGF-1 signaling, while
providing novel insights into the regulation of tumorigenesis by a hominoid-specific protein.
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Introduction
Knowledge of genes that are specific to humans is likely to shed
light on our understanding of human physiology and pathology.
TBC1D3 is a hominoid-specific gene that maps to human
chromosome 17 [1]. Like many hominoid-specific genes, TBC1D3
appears to have evolved in the primate lineage by segmental
duplication [2]. Recent work indicates that TBC1D3 is a multi-
copied gene in humans [3,4], with variable copy numbers in
different individuals [5]. Although TBC1D3 is one of the first
hominoid-specific genes which have been examined at the protein
level [6,7], little is known about its function. Initial studies indicate
that TBC1D3 is linked to cell proliferation and signaling by growth
factor receptors. Indeed, signals generated by the EGF receptor
(EGFR) are substantially amplified by TBC1D3 expression, in part,
because thedegradationof the receptoris delayed duetosuppressed
EGFR ubiquitination. TBC1D3 expression also enhances Ras
activation in growth factor-stimulated and unstimulated cells [6].
In this study, we focused on the role of TBC1D3 in regulating
the mTOR-S6K-IRS-1 axis within the insulin signaling pathway.
Because of its central role in cell proliferation and glucose
homeostasis, the signaling pathway controlled by insulin and other
growth factors is one of the most intensely investigated cellular
pathways. Insulin resistance precedes the development of type 2
diabetes, and in addition, hyper-activation of the pathway is
associated with several proliferative diseases [8,9].
Insulin receptor signaling is mediated by the recruitment of
numerous adapters and among the most important is IRS-1. IRS-
1-mediated insulin signaling is attenuated by IRS-1 ubiquitination
and degradation [10]. Key residues in IRS-1, which are essential
for its ubiquitination, include S636/639, a site that is phosphor-
ylated, directly or indirectly, by S6K. S6K, in turn, is
phosphorylated and activated by mammalian target of rapamycin
(mTOR) [11].
In mammalian cells, at least two proteins are regulated by the
activity of mTOR: 4E-BP1 and S6K, which are involved in the
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31225initiation of protein translation and are regulated by Ser/Thr
phosphorylation [8,12]. S6K is also regulated by PP2A, a family of
abundantly expressed serine-threonine phosphatases that plays an
important role in diverse cellular functions [13,14].
Using insulin-sensitive human cell lines, we report that
TBC1D3 expression suppresses IRS-1 ubiquitination and delays
degradation by selectively enhancing the dephosphorylation of
S6K at T389. We provide evidence that a specific PP2A
regulatory subunit B56c, recently shown to dephosphorylate
S6K at T389 [15], is a target of TBC1D3. TBC1D3 delays
IRS-1 degradation by accelerating the dephosphorylation/inacti-
vation of S6K thereby enhancing insulin signaling.
This study was aimed at exploring the effect of TBC1D3 on
insulin/IGF-1 signal transduction pathway. Our findings indicate
that TBC1D3 expression enhances the intensity and duration of
the insulin/IGF-1 signaling cascade.
Results
Insulin signaling pathway is positively regulated by
TBC1D3
In previous studies, we demonstrated that TBC1D3 expression
has a powerful effect on cell proliferation that is further enhanced by
epidermal growth factor (EGF) [6]. To determine whether TBC1D3
modulates signal transduction through the insulin receptor, we
examined insulin signaling in HepG2 cells (American Type Culture
Collection, Manassas, VA), a well-studied human hepatocellular
carcinoma cell line. HepG2 cells were transfected with myc-
TBC1D3 and incubated with 10 nM insulin. Phosphorylation levels
of Akt on S473, a well-established downstream marker for activation
of insulin receptor signaling, were monitored by Western blotting.
Total cellular contents of Akt were used to normalize the results in
each sample. Figure 1A shows that insulin-induced phosphorylation
of Akt:S473 is significantly increased in cells expressing TBC1D3,
suggesting increased activation of insulin signaling.
To exclude misleading phenotypes due to over-expression, we
utilized RNA interference to suppress endogenous TBC1D3. Two
different siRNAs directed against TBC1D3 (siRNA#1 and
siRNA#2) were transfected into HepG2 cells. A scrambled,
irrelevant siRNA (scr) was used as a negative control. 36 hours
later, cells were serum-starved and stimulated with insulin
(10 nM).
We were not able to detect the expression of endogenous
TBC1D3 protein, since a reliable anti-TBC1D3 antibody is
currently unavailable. Thus, a quantitative real-time PCR was
carried out to determine the efficiency of siRNA-mediated target
suppression. Both siRNA duplexes decreased mRNA levels of
TBC1D3 by 60%–70% (data not shown). No off-target silencing
effect was observed.
Consistent with the results obtained when over-expressing
TBC1D3, silencing of TBC1D3 abrogated the activation of Akt
following insulin stimulation (Figure 1B). Collectively, these results
establish that TBC1D3 is a positive regulator of the insulin
signaling pathway.
TBC1D3 modulates IRS-1 phosphorylation
The insulin receptor (IR) is activated by autophosphorylation on
tyrosine residues that function as docking sites for adaptor
proteins. Among these are the insulin receptor substrate (IRS)
proteins. IRS-1, which is widely expressed, is the most-well-
characterized member of the IRS family. IRS proteins are rapidly
recruited to the insulin receptor and activated by tyrosine
phosphorylation following insulin stimulation [16,17]. While
phosphorylation on tyrosine residues is required for IRS-1
activation, serine phosphorylation plays an important role in both
the propagation and the attenuation of insulin signaling [18–20].
To gauge the effect of TBC1D3 expression on IRS-1
phosphorylation, IRS-1 and myc-TBC1D3 were co-expressed in
Hek293 cells (American Type Culture Collection, Manassas, VA).
Total cell lysates were prepared after insulin treatment and IRS-1
Figure 1. TBC1D3 increases signaling through the activation of insulin pathway. (A) HepG2 cells transfected with myc-TBC1D3 or empty
vector were serum-starved, and stimulated with insulin (10 nM) for the indicated times. Phosphorylation and protein levels of Akt were analyzed by
Western blotting. (Right panel) Quantification data of Akt:S473 phosphorylation normalized to Akt protein levels (* p,0.05, ** p,0.01). (B) HepG2
cells were transfected with two different TBC1D3 siRNA oligos (50 nM) (si#1 and si#2), scramble siRNA (scr) or untransfected (ctr). After 36 h, cells
were serum-starved and stimulated with 10 nM insulin for the indicated times and analyzed by Western blotting with the listed antibodies. (Right
panel) Quantification data of Akt:S473 phosphorylation normalized to Akt protein levels (* p,0.05). The data are presented as means 6 SD of three
independent experiments.
doi:10.1371/journal.pone.0031225.g001
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phospho-specific antibodies. Total IRS-1 levels were measured
and used to normalize and quantify the results in each sample.
Over-expression of TBC1D3 did not affect insulin-stimulated
IRS-1 phosphorylation on tyrosine residues (data not shown),
however it led to a reduced phosphorylation of recombinant IRS-1
on S307, S312 and S636/639 in response to insulin, when
compared to control cells (Figure 2A). These observations were
confirmed by measurements of endogenous IRS-1: S636/639
phosphorylation in TBC1D3-expressing cells, which was signifi-
cantly lower after 5 or 30 min of insulin stimulation (Figure 2B).
Similar data were obtained on endogenous IRS-1 phosphorylation
when cells were treated with IGF-1 instead of insulin (data not
shown). However, TBC1D3 appeared to have no effect on IRS-1:
S1101 phosphorylation, showing a phosphorylation pattern similar
to control cells (data not shown).
A recent publication by Ye and colleagues, found IRS-1:S270 as
a novel IRS-1 phosphorylation site that may be involved in
regulating the phosphorylation of other serine residues by TNF-a
[21]. Our results demonstrate that insulin stimulation of
phosphorylation at IRS-1:S270 is also significantly reduced in
TBC1D3-over-expressing cells. Collectively, these findings indi-
cate that IRS-1 serine phosphorylation, but not tyrosine
phosphorylation, is selectively reduced in the presence of
TBC1D3.
TBC1D3 over-expression delays IRS-1 ubiquitination and
degradation
To understand the functional consequences of decreased IRS-1
serine phosphorylation by TBC1D3 over-expression, we next
studied the kinetics of IRS-1 degradation. To test whether
TBC1D3 delays this process, DU145 cells (American Type
Culture Collection, Manassas, VA) transiently transfected with
myc-TBC1D3 or empty vector were serum-starved, and incubated
with insulin for the indicated times. Total cellular levels were
quantified by Western blotting and were used to normalize the
amount of protein remaining at each time point. Cycloheximide
(25 mg/ml) was added to block de novo IRS-1 synthesis.
Control cells showed a rapid degradation of IRS-1; about 50%
of the IRS-1 signal was lost after 2 hours of insulin treatment
(Figure 3). However, IRS-1 degradation was significantly delayed
in cells expressing TBC1D3; only about 10% of the IRS-1 protein
was degraded after 2 hours, and only after 4 hours was there a
substantial reduction comparable to control cells (,50%).
In agreement with these results, over-expression of TBC1D3
has also resulted in suppression of IRS-1 ubiquitination (data not
shown), suggesting that TBC1D3 regulates IRS-1 turnover via
modulation of its ubiquitination status.
p70 S6K activation is reduced in TBC1D3 expressing cells
mTOR is a serine/threonine protein kinase that regulates cell
growth and proliferation through a rapamycin-sensitive pathway
involving the regulatory proteins p70 S6K and the eukaryotic
initiation factor 4E-binding protein-1 (4EBP1) [11]. Several
independent studies reported that S6K is involved in the
phosphorylation of IRS-1 at multiple serine residues, including
S307, S312, S270 and S636/639 [21–24]. To explore the
mechanism underlying the decreased IRS-1 phosphorylation in
TBC1D3-expressing cells, we first examined the ability of insulin
to stimulate phosphorylation of S6K at T389, a residue that is
critical for its activation [25]. As shown in Figure 4A, insulin
stimulation of S6K:T389 phosphorylation is robust, increasing
Figure 2. TBC1D3 selectively decreases IRS-1 Serine phosphorylation. (A) Empty vector or myc-TBC1D3 was co-transfected with pCIS2-IRS-1
in Hek293 cells. Cells were stimulated with insulin (10 nM) for 30 min. Phosphorylation and protein levels of IRS-1 were analyzed by Western blotting.
(Right panel) Quantification data of IRS-1 phosphorylation normalized to IRS-1 protein levels (* p,0.05, ** p,0.01). (B) Hek293 cells were transfected
with myc-TBC1D3 or empty vector, serum-starved and stimulated with insulin (10 nM) for 5 or 30 min. Phosphorylation of endogenous IRS-1:S636/
639 was analyzed by Western blotting. (Right panel) Quantification data of endogenous IRS-1 phosphorylation normalized to IRS-1 protein levels
(* p,0.05). The data are presented as means 6 SD of three independent experiments.
doi:10.1371/journal.pone.0031225.g002
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TBC1D3-expressing cells, S6K:T389 phosphorylation in response
to insulin is reduced. The effect of TBC1D3 on S6K:T389
phosphorylation is modest, however it is statistically significant.
These findings suggested that the mTOR signaling pathway may
be involved in the reduced serine phosphorylation and degrada-
tion of IRS-1, through a defect in S6K activation.
To support this hypothesis, we next determined whether
mTOR, the kinase responsible for S6K activation, was defective
by evaluating the phosphorylation status of the other mTOR
substrate, 4EBP1. However, phosphorylation of 4EBP1 was
normal and similar in both TBC1D3-expressing and control cells
after insulin treatment (Figure 4B). Moreover, when the cells were
pre-treated with rapamycin for 2 h before insulin stimulation, both
S6K and 4EBP1 phosphorylation signals were completely
quenched, confirming that mTOR pathway was not defective
and fully functional under these experimental conditions.
TBC1D3 regulates PP2A activity
Reduced S6K phosphorylation in cells expressing TBC1D3
could be due to decreased mTOR kinase activity or increased
phosphatase activity. Several recent studies have linked PP2A to
the regulation of S6K [13,15,26,27]. To determine if TBC1D3
modulates PP2A activity on S6K, HepG2 cells were transfected
Figure 3. TBC1D3 expression blocks IRS-1 degradation. IRS-1 degradation is delayed in cells expressing TBC1D3. DU145 cells transfected with
myc-TBC1D3 or empty vector were serum-starved, and stimulated with insulin (10 nM) for the indicated times. Protein levels of IRS-1 were analyzed
by Western blotting. (Right panel) Quantification data of IRS-1 normalized to GAPDH protein levels. The value of IRS-1 at time 0 was set at 1.0. The
data are presented as means 6 SD of three independent experiments.
doi:10.1371/journal.pone.0031225.g003
Figure 4. TBC1D3 reduces S6K activation, but does not affect mTOR-C1 pathway. (A) HepG2 cells transfected with myc-TBC1D3 or empty
vector were serum-starved, and stimulated with insulin (10 nM) for 30 min. Phosphorylation and protein levels of S6K were analyzed by Western
blotting. (Right panel) Quantification data of S6K:T389 phosphorylation normalized to S6K protein levels (** p,0.01). (B) HepG2 cells transfected with
myc-TBC1D3 or empty vector were serum-starved, pre-treated with Rapamycin (50 nM) for 2 h, and stimulated with insulin (10 nM) for 30 min.
Phosphorylation and protein levels of 4EBP1 and S6K were analyzed by Western blotting. (Right panel) Quantification data of 4EBP1 phosphorylation
normalized to GAPDH protein levels. The data are presented as means 6 SD of three independent experiments.
doi:10.1371/journal.pone.0031225.g004
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insulin stimulation. OA is a cell permeable inhibitor that
selectively inhibits PP2A when used at low concentrations
(IC50=0.51 nM) [28,29]. The analysis of phospho-S6K revealed
that, as in previous results, S6K activation was significantly
reduced in TBC1D3-expressing cells, when compared to control
cells (Figure 5A). Treatment with OA dramatically increased
phosphorylation, restoring it to the control levels (Figure 5A, bar
graph). The concentrations assayed (20 and 50 nM) were too low
to have any effect over PP1, another phosphatase of the same
family [28]. Additionally, we were able to exclude the involvement
of PP2B/calcineurin by using specific inhibitors FK506 and
Calyculin A (data not shown).
Direct verification of PP2A enhanced activation was detected in
vitro using a specific synthetic phosphopeptide (Figure 5B). PP2A
enzyme immunoprecipitated from TBC1D3-expressing cells
showed a much higher phosphatase activity, relative to that in
control cells (.2.5-fold increase). The activity was almost
completely abolished when the cells were pre-treated with OA,
confirming that the PP2A activity was specifically modulated by
TBC1D3 expression. Biochemical experiments were used to rule
out enhanced expression levels of the different PP2A subunits
when over-expressing TBC1D3 (data not shown).
TBC1D3 modulates the effect of PP2A B56c on S6K:T389
phosphorylation
PP2A B56c, a regulatory B9 subunit of PP2A encoded by
PPP2R5C gene, has been identified as a specific negative regulator
of S6K phosphorylation [15]. To explore whether TBC1D3
modulates PP2A activity on S6K phosphorylation through the
specific PP2A regulatory subunit B56c, PP2A B56c-knockdown
DU145 cells were prepared using specific shRNAs. Western
blotting results indicated that PP2A B56c protein expression was
suppressed by nearly 70% in the presence of three independent
PP2A B56c shRNAs compared with control shRNAs (Figure 6A).
No off-target silencing effects were observed. Control and PP2A
B56c-silenced cells were transfected with myc-TBC1D3 before
insulin stimulation.
In control cells, analysis of S6K:T389 phosphorylation levels
indicates that S6K activity is dramatically elevated by insulin
treatment as expected, and that S6K:T389 phosphorylation is
modestly reduced in the presence of TBC1D3, confirming the
results in Figure 4. Consistent with previously published findings
[15], a significant increase in the level of phosphorylated S6K
protein was observed in the PP2A B56c-knockdown cells.
Similar to insulin-treated control cells, TBC1D3 expression
significantly reduced S6K:T389 phosphorylation in PP2A B56c-
knockdown cells. In the insulin-treated PP2A B56c-knockdown
cells, there was a significant increase in S6K:T389 phosphoryla-
tion (compared with the absence of insulin treatment) but
TBC1D3 expression was less effective in reducing S6K:T389
phosphorylation.
To confirm the role of S6K in TBC1D3-suppression of IRS-1
phosphorylation, we took advantage of a rapamycin-resistant
mutant of S6K, S6K-ED3E. We examined the effect of TBC1D3
on IRS-1:S636/639 phosphorylation in cells transfected with IRS-
1 and with either TBC1D3 alone or TBC1D3 and S6K-ED3E.
Following stimulation with insulin, IRS-1 was immunoprecipitat-
ed, resolved by SDS-PAGE and blotted with the specific antibody
against phospho-IRS-1:S636/639. The results are presented in
Figure 6B. TBC1D3 suppressed the phosphorylation of IRS-1 at
S636/639 before and after insulin treatment. However, following
transient expression of the S6K-ED3E construct, expression of
TBC1D3 was unable to suppress insulin-stimulated IRS-1:S636/
639 phosphorylation indicating that S6K is the likely target of
TBC1D3.
We speculated that TBC1D3 modulates the effect of PP2A
B56c on S6K:T389 phosphorylation by functionally interacting,
directly or indirectly, with PP2A B56c. To verify this possibility, a
Figure 5. PP2A activity is increased in TBC1D3-expressing cells. (A) HepG2 cells transfected with myc-TBC1D3 or empty vector were serum-
starved, and pre-treated with OA at various concentrations for 30 min, prior to insulin stimulation. Phosphorylation and protein levels of S6K were
analyzed by Western blotting. (Right panel) Quantification data of S6K:T389 phosphorylation normalized to S6K protein levels (* p,0.05, ** p,0.01).
(B) HepG2 cells transfected with myc-TBC1D3 or empty vector were serum-starved, and pre-treated with or without OA (50 nM) for 30 min before
insulin stimulation. PP2A activation was assayed in vitro using the synthetic phosphopeptide K-R-pT-I-R-R, as described in Experimental Procedures
(** p,0.01). The data are presented as means 6 SD of three independent experiments.
doi:10.1371/journal.pone.0031225.g005
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determine whether TBC1D3 interacts with endogenous B56c.
Hek293 cells transfected with empty vector or myc-TBC1D3 were
lysed and immunoprecipitated with anti-myc or anti-B56c
antibodies followed by SDS-PAGE and Western blotting. As
shown in Figure 6C, endogenous B56c was specifically pulled
down in TBC1D3-expressing samples incubated with anti-myc
antibody, but not control Hek293 cells, while TBC1D3 was
precipitated in TBC1D3-expressing samples incubated with anti-
B56c antibody. These results suggest that TBC1D3 and B56c
interact with each other while pointing to the need for further
studies to define the structural basis for functional interactions.
Discussion
TBC1D3 appears to have evolved along the hominoid-lineage
35 million years ago by segmental duplication [2]. It was identified
by a set of innovative experiments involving human DNA
transfected into and carried by mouse tumors [30] and shown
subsequently to be an oncogene by Pei et al [1]. More recently,
Hatanaka et al [31] using a human gall bladder cancer cDNA
library, identified TBC1D3 as an oncogene. Hodzic et al [3] and
Paulding et al [2] identified multiple transcripts of TBC1D3 in
humans and revealed that multiple TBC1D3 paralogs are
expressed in insulin-sensitive, as well as other tissues. Recent work
by Eichler and colleagues [5] on copy number variation in a large
cohort of humans from different ethnic backgrounds revealed a
surprising finding – European genomes encode ,8–20 copies of
TBC1D3, Asian genomes ,15–30 copies and African (Yoruba)
genomes ,30–55 copies. The importance of this is unclear but it
seems reasonable to speculate that TBC1D3 has been subjected to
some unknown positive evolutionary pressure. Although absent
from the mouse and other model organisms, TBC1D3 is found in
the Chimp genome as a single copy gene [4]. Interestingly, the
Neanderthal draft genome encodes TBC1D3 [32] although
apparently also at low copy number. Our initial work [6] and
that of Fritolli et al [7], indicates that TBC1D3 expression
enhances cell proliferation and alters the signaling properties of
growth factor receptors. EGF-stimulated pinocytosis was increased
[7] and EGFR trafficking and degradation were delayed [6]
suggesting that phosphorylation and/or ubiquitination of the
EGFR were altered by TBC1D3 expression.
There has been a growing realization that signaling abnormal-
ities within nutrient signaling pathways can lead to abnormal cell
growth and cancer. The insulin/IGF-1 signaling pathway and the
mTOR/S6K cascade defines a metabolic network that integrates
glucose metabolism and energy balance with cell proliferation and
survival [33]. Our current study provides evidence for a regulatory
role for TBC1D3 in insulin signaling with a putative link to cell
proliferation.
We report that TBC1D3 expression enhances the signaling
properties of insulin receptor as determined by standard assay, the
Figure 6. PP2A B56c mediates S6K phosphorylation in response to TBC1D3 expression. (A) DU145 cells with GFP (control) or PP2A B56c
knockdown were transfected with myc-TBC1D3 or empty vector, serum-starved, and stimulated with insulin (10 nM) for 30 min. Phosphorylation and
protein levels of S6K were analyzed by Western blotting. (Right panel) Quantification data of S6K:T389 phosphorylation normalized to S6K protein
levels (* p,0.05, ** p,0.01). (B) Reduction of IRS-1:S636/639 phosphorylation induced by TBC1D3 expression is rescued by a rapamycin-resistant
mutant of S6K. pCIS2-IRS-1, myc-TBC1D3 or empty vector were co-transfected with HA-S6K-ED3E or vector in DU145 cells. Cells were stimulated with
insulin (10 nM) for 0, 5 or 30 min after serum-starvation. Phosphorylation and protein levels of IRS-1 were analyzed by Western blotting. (Right panel)
Quantification data of IRS-1:S636/639 phosphorylation normalized to IRS-1 protein levels (* p,0.05, ** p,0.01). The data are presented as means 6
SD of three independent experiments. (C) TBC1D3 co-immunoprecipitates with PP2A B56c. Hek293 cells were transfected with myc-TBC1D3 or empty
vector. Cell lysates were immunoprecipitated with anti-myc or anti-B56c antibodies, respectively. Co-IP samples were separated by SDS-PAGE and
analyzed by Western blotting with specific antibodies.
doi:10.1371/journal.pone.0031225.g006
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suppressed the activation of Akt by insulin. Degradation of
endogenous IRS-1 was suppressed following insulin treatment in
cells expressing TBC1D3 (Figure 3). Since serine phosphorylation
is key to IRS-1 degradation, these experiments led us to consider
IRS-1 phosphorylation as a prime TBC1D3 target. More than a
dozen different kinases are known to phosphorylate IRS-1 in
addition to receptor kinase-driven tyrosine phosphorylation [34].
These phosphorylation sites orchestrate IRS-1 interaction with
growth factor receptors, its activation of Ras via binding of Grb2
and SOS [35,36] and its translocation to the nucleus [37].
IRS-1 degradation following ubiquitination is part of the
negative feedback loop designed to initiate and limit nutrient
uptake and growth [20]. S6K phosphorylates IRS-1 on S636/639,
a key residue for IRS-1 degradation. It remains unclear whether
IRS-1:S636/639 is phosphorylated directly by S6K or not.
However, phosphorylation at IRS-1:S270 has been reported to
favor subsequent phosphorylation on S307, S636/639, and S1101
of IRS-1 in response to insulin stimulation (although S1101 may
be phosphorylated by PKC h). Using site-specific antibodies, we
found that TBC1D3 expression suppressed serine phosphorylation
at all of the above sites except for IRS-1:S1101.
In their pioneering study, Pan and colleagues [10] reported that
Cul7 ubiquitinates IRS-1 and that phosphorylation of IRS-1 by
mTOR/S6K is important for Cul7 recognition of IRS-1. These
findings have placed IRS-1 and Cul7 in the center of a major
growth factor signaling and cell proliferation pathway
[16,34,38,39]. The physiological importance of IRS-1 goes well
beyond that of insulin and IGF signaling. It is associated more
broadly with growth and shown to facilitate tumorigenesis. IRS-1
also operates as a signal-transducing element in the nucleus where
it binds to upstream binding factor 1, which is involved in rRNA
synthesis [37]. Over-expression of IRS-1 has been associated with
breast cancer, and estrogen has been shown to enhance
transcription/translation of IRS-1 [40–42].
To explore the mechanisms of TBC1D3-induced suppression of
IRS-1phosphorylation,wefocusedontheeffectofTBC1D3onS6K
activation. S6K is activated by mTOR signaling via phosphorylation
on T389 and inactivated by PP2A-dependent dephosphorylation.
Expression of TBC1D3 can suppress phosphorylation and/or
enhance dephosphorylation of S6K at T389.
To test the hypothesis that TBC1D3 enhances the dephosphor-
ylation and inactivation of S6K in PP2A-dependent manner, we
took advantage of the potent PP2A inhibitor OA. OA specifically
inhibits the protein phosphatases 1 (PP1) and 2A (PP2A) [28]. PP2A
is inhibited by OA at concentrations of 1–2 nM, whereas PP1 is
much less sensitive. OA is also cell-permeable permitting its use in
intact cells [1,3]. As shown in Figure 5A, OA reversed the inhibitory
effect of TBC1D3 on S6K dephosphorylation at T389, suggesting
that PP2A is a target of TBC1D3.
PP2A is a large family of heterotrimeric enzymes that account
for the majority of total serine/threonine phosphatase activity in
most tissues and cells [43]. Although a dimer comprised of a 65-
kDa scaffolding (A) subunit and a 36-kDa catalytic (C) subunit
constitutes the core enzymatic activity of PP2A, the binding of a
third regulatory (B) subunit to the AC core enzyme regulates PP2A
activity, cellular localization, and substrate specificity [43]. PP2A
can exist in cells as either the AC core complex or an ABC
heterotrimeric holoenzyme that is the dominant form in most cells.
In humans there are at least 16 B regulatory subunits that can be
classified into B (B55), B9 (B56), B0, and B- families based on
sequence similarity [44]. Studies by Chen et al [45] showed that
down-regulation of B56c together with expression of the SV40
small T antigen (ST) reduced PP2A activity by 43%, suggesting
PP2A-B56c holoenzyme may represent a substantial proportion of
the total PP2A activity in vivo. The assembly and function of the
active PP2A complex is regulated by methylation [46], by
phosphorylation and by factors such as the protein a4 [47] and
ST [44]. It is possible that TBC1D3 alters any one of these
regulatory post-translational modifications by displacing one or
more factors known to interact with PP2A to enhance its effect on
PP2A-dependent dephosphorylation of S6K:T389.
A provocative study by Hahn et al [15] showed that PPP2R5C,
encoding the B56c regulatory subunit of PP2A, acts as a specific
negative regulator of S6K phophorylation in flies and humans.
This discovery prompted us to examine to role of PP2A B56c in
TBC1D3 suppression of S6K activation. As shown in Figure 6A,
silencing of B56c resulted in enhanced S6K:T389 phosphoryla-
tion (confirming earlier reports). TBC1D3 expression signifi-
cantly reduced S6K:T389 phosphorylation in these cells.
S6K:T389 phosphorylation in PP2A B56c-silenced cells was
further enhanced by insulin treatment. However, TBC1D3 was
much less effective in reducing S6K:T389 phosphorylation in
PP2A B56c-silenced cells. These findings suggest that insulin was
more effective in driving S6K:T389 phosphorylation than
TBC1D3 was in enhancing dephosphorylation at low levels of
PP2A B56c.
To confirm that the target of TBC1D3 was S6K and not a
downstream event (e.g., the direct dephosphorylation of IRS-
1:S636/639 by PP2A), we took advantage of a rapamycin-resistant
mutant of S6K called S6K-ED3E [48]. Expression of S6K-ED3E
permitted the insulin sensitive stimulation of IRS-1:S636/639
phosphorylation but abolished the TBC1D3 inhibitory effect.
Clearly, other unknown factors are at play such as the effect of
TBC1D3 expression on overall PP2A activity (Figure 5B). Human
PP2A B56c has at least three differentially spliced isoforms, B56c1,
B56c2, and B56c3 [49] and eventhoughtheintroductionof specific
shRNAs should target all three isoforms, we were unable to confirm
theknockdown ofB56c1sincethe antibodyused inourexperiments
for detecting B56c only recognizes the B56c2 and B56c3 isoforms.
However, we confirmed the interaction between TBC1D3 and
B56c by co-immunoprecipitation assays (Figure 6C).
Taken together, the reversal of TBC1D3-enhanced S6K
phosphorylation by OA and by silencing PP2A B56c supports
the conclusion that PP2A B56c is a prime downstream target of
TBC1D3. Based on these early observations, we offer a working
model (Figure 7) to guide further experimentation. In this model,
insulin (or IGF1) activates IRS-1 and the Akt pathway to enhance
nutrient accumulation. As proposed by Pan and colleagues [10], a
negative feedback loop is created via the mTOR/S6K pathway to
limit the response to insulin by enhancing the Cul7-dependent
degradation of IRS-1. We propose that TBC1D3 sustains the
response to insulin by delaying or suppressing the ubiquitination
and degradation of IRS-1. This is accomplished by the combined
action of TBC1D3 and PP2A B56c that results in deactivating
S6K by S6K:T389 dephosphorylation.
Notably, previous work showed that TBC1D3 also suppressed
the recruitment of the E3 ligase CBL to the EGF receptor thereby
suppressing the ubiquitination and degradation of the activated
EGFR [6]. It is possible that by interacting with the PP2A B56c
complex, TBC1D3 may lead to selective de-phosphorylation of
key elements involved in insulin, EGF and in other growth factor
signaling pathways, leading to aberrant signaling and growth.
The human genome encodes a significant number of genes that
are either human- or hominoid-specific and that have no known
orthologs in lower organisms [50]. These genes and the proteins
they encode are likely to reveal information about human
evolution and possibly provide insight into many questions about
TBC1D3, S6K, PP2A and IRS-1
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upstream regulator mTOR and IRS-1 have been shown to play a
role in aging and lifespan in model organisms [51]. By
demonstrating that TBC1D3 modulates insulin signaling by
altering S6K-dependent phosphorylation of IRS-1 via the B56c
subunit of PP2A, we forward the hypothesis that TBC1D3 plays a
role, perhaps central, in human metabolism.
Materials and Methods
Reagents
Monoclonal a-tubulin, human insulin and MG132 were
purchased from Sigma-Aldrich (St. Louis, MO). Antibodies
against PKB/Akt (Akt) as well as phospho-Akt S473, phospho-
MAPK, total MAPK, phospho-4EBP1, phospho-S636/639,
phospho-S1101 and phospho-S307 of IRS-1, S6K and phospho-
S6K were obtained from Cell Signaling Technology (Beverly,
MA). Phospho-S270 of IRS-1 and PI3k-p85a antibody were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibody to phospho-S312 of IRS-1 was acquired from Biosource
(Camarillo, CA). Monoclonal antibody against phospho-Tyr of
IRS-1 was purchased from BD Transduction Laboratories (San
Jose, CA). IRS-1 antibody was provided by Dr. Mike Mueckler,
Washington University (St. Louis, MO). The monoclonal antibody
directed against the C-terminal 50 amino acids of TBC1D3 was
generated by the Hybridoma Center, Washington University (St.
Louis, MO). A rabbit polyclonal antibody against PP2A B56c3
was a gift from Dr. Bill Hahn, Dana Farber Cancer Institute
(Boston, MA). pCLS2-IRS-1 construct was a gift from Dr.
Jianping Ye, National Institutes of Health (Bethesda, MD).
Rapamycin was purchased from Enzo Life Sciences (Plymouth
Meeting, PA). pRK7-HA-S6K-ED3E was a gift from Dr. Tony
Hunter, Salk Institute (La Jolla, CA) [48].
PP2A B56c and TBC1D3 silencing
PP2A B56c was successfully suppressed using three different
shRNAs against PP2A B56c (Gene ID: NM_ 002719.X-385s1c1,
NM_002719.X-1481s1c1 and NM_002719.X-1348s1c1) [14],
provided by Genome Center at Washington University in St.
Louis. Briefly, DU145 cells were plated at about 50% confluency
and transfected with pLKO.1-puro shGFP or pLKO.1-puro
vectors containing shRNAs targeting PP2A B56c using Lipofecta-
mine 2000. Suppression of PP2A B56c was assessed after 72 hours
of incubation by Western blotting [45]. TBC1D3 was successfully
knocked down using two different siRNA against TBC1D3
(Ambion, Inc; Silencer Select Pre-designed siRNA ID# s230583
and ID# s230584). Briefly, cells were transfected with TBC1D3
siRNA (50 nM final concentration) or irrelevant siRNA (siGLO
control siRNA, Dharmacon) using Lipofectamine RNAiMax and
were used for the appropriate experiments after 36 hours. RNA
extracted from cells using RNeasy (Qiagen, MA) was used to
detect TBC1D3 transcript levels by quantitative real-time PCR.
Briefly, first-strand cDNA was produced using SuperScript III
Reverse Transcriptase (Life Technologies, CA) with random
primers. 1 mg of total RNA was used for each reverse transcription
reaction (20 ml). For the real-time PCR, 2 ml of the 20 ml reverse
transcription reaction mixture were used. Forward primer 59- GC-
ATCGACCGGGACGTAAG- 39; reverse primer 59- CCTCCG-
GGTTGTACTCCTCAT -39, corresponding to nucleotide 431
and 550, respectively), using Platinum Taq DNA Polymerase Hi-
Fi (Life Technologies, CA). Real-time PCR was carried out using
an ABI PrismH 7000 Sequence Detection System (Life Technol-
ogies, CA). Cycling conditions were as follows: denaturation (95uC
for 5 min), amplification and quantification (95uC for 30 s, 55uC
for 30 s, and 72uC for min), repeated 40 times. Each sample was
run in triplicate.
SDS-PAGE and Western blotting
To obtain cell lysates, cell monolayers were washed with PBS
and lysed in ice-cold lysis buffer (PBS, 1% Triton X-100, 1 mM
phenylmethylsulfonylfluoride, 2 mg/ml pepstatin A, 2 mg/ml
leupeptin, and 2 mg/ml aprotinin). Cell lysates were clarified by
centrifugation and proteins were resolved by SDS-PAGE and
transferred to nitrocellulose membranes, which were blocked and
probed with the indicated antibodies. To determine relative
protein amounts, three representative exposures for each sample
were quantified using AlphaEaseFc software (Alpha Innotech
Corporation, San Leandro, CA).
Signaling and degradation assays
Protein phosphorylation and IRS-1 degradation were measured
in cells serum-starved for 5 hours. Cells were incubated in the
presence of insulin (10 nM) at 37uC, washed with ice-cold PBS
and lysed. Proteins were separated by SDS-PAGE and analyzed
by Western blotting.
Immunoprecipitation
Cells were lysed in ice-cold immunoprecipitation buffer
containing 20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1% Triton
X-100, 1 mM EGTA, 1 mM EDTA, 2.5 mM sodium pyrophos-
phate, 1 mM b-glycerolphosphate, 1 mM NaF, 1 mM sodium
orthovanadate plus protease inhibitors. Extracts were immuno-
precipitated by incubation with the appropriate antibody followed
by immobilization on Protein G-Sepharose beads (Sigma). Beads
were resuspended in sample buffer and analyzed by SDS-PAGE
and Western blotting.
PP2A activity assay
PP2A activity was assayed using PP2A Immunoprecipitation
Phosphatase Assay Kit (Upstate). Briefly, PP2A catalytic (C)
subunit was immunoprecipitated from 300 mg of cell lysates using
anti-PP2A C subunit antibody (clone1D6, Upstate). Enzymatic
activity was measured by incubation of the immunoprecipitated
PP2A C subunit with the synthetic phosphopeptide K-R-pT-I-R-
R following manufacturer’s instructions.
Figure 7. Model for the regulation of IRS-1 degradation by
TBC1D3 expression. We propose that TBC1D3 suppresses the
degradation of IRS-1 by regulating the phosphorylation of S6K at
T389. In this model, mTOR phosphorylates S6K in response to insulin
signaling. TBC1D3 interacts, directly or indirecly, with PP2A B56c to
enhance the dephosphorylation of S6K:T389 thereby reducing the S6K-
dependent phosphorylation of IRS-1 at key sites which are required for
IRS-1 ubiquitination and degradation.
doi:10.1371/journal.pone.0031225.g007
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All experiments presented were repeated a minimum of three
times. Results were expressed as mean values 6 standard error
(mean 6 SE). Student’s t-test or one-way analysis of variance
(ANOVA) was performed to calculate statistical significance.
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